- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
May 12, 2022Robins Kaplan Practice Group, Attorney Recognized in Elite Trial Lawyers Awards
-
May 9, 2022Six Partners Recognized as “IP Stars” by Managing Intellectual Property
-
May 4, 2022Robins Kaplan LLP Relocates Silicon Valley Office
-
May 26, 2022Democracy’s Last Line of Defense
-
June 2, 2022Hennepin County Bar Foundation 2022 Bar Benefit
-
June 2, 2022Lawyers Concerned for Lawyers 2022 Stepping Up Breakfast
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
May 5, 2022Antitrust Law As A Tool Against Privacy Abuses
-
May 24, 2022Broadcom Weighing $60B Bid for Hybrid Cloud Co. VMWare
-
May 20, 2022China Unexpectedly Cuts Key Benchmark Rate in Attempt to Jump-Start Flagging Economy
-
May 19, 2022Inflation-Battered Retailers Spur Vast Market Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Hatch-Waxman Litigation Venue Update Post-Google
May 06, 2020
Patent litigants often fight over personal jurisdiction and venue. This battle is particularly high-stakes in Hatch-Waxman litigation, because the fight between brand name and generic drug makers arises prior to Food and Drug Administration approval and launch of the accused product. The brand often can maintain its market exclusivity during the pendency of the case; thus, even if a generic eventually wins on the merits, a slow case can effectively be a win for the brand.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.